Related Experiment Videos
Hyperlipidemia and its management in renal disease
1Division of Nephrology, Hennepin County Medical Center, University of Minnesota Medical School, Minneapolis 55415, USA.
Current Opinion in Nephrology and Hypertension
|March 1, 1996
Summary
Dyslipidemia is common in patients with kidney disease and contributes to cardiovascular issues. Newer lipid-lowering drugs are safe and effective for these patients, enabling further research.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Dyslipidemia is prevalent in patients with renal disease.
- It is a significant contributor to cardiovascular disease (CVD) incidence.
- Dyslipidemia may also accelerate progressive renal injury.
Purpose of the Study:
- To review the safety and efficacy of newer antilipemic agents in patients with renal disease.
- To highlight the potential for large-scale clinical trials on lipid-lowering strategies in this population.
Main Methods:
- Review of recent studies on antilipemic agents in renal disease patients.
- Analysis of safety and efficacy data.
Main Results:
- Newer antilipemic agents demonstrate safety and effectiveness in patients with renal disease.
- These findings support the feasibility of conducting large, controlled clinical trials.
Conclusions:
- Lipid-lowering strategies can be safely implemented in patients with renal disease.
- Further research is warranted to investigate the impact of these strategies on CVD and renal disease progression.